DLD Asset Management LP Makes New $250,000 Investment in DBV Technologies S.A. $DBVT

DLD Asset Management LP purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $250,000. DLD Asset Management LP owned approximately 0.07% of DBV Technologies at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. New York State Common Retirement Fund bought a new position in DBV Technologies during the 3rd quarter worth about $34,000. Nan Fung Trinity HK Ltd. purchased a new position in DBV Technologies during the 2nd quarter valued at about $340,000. Artisan Partners Limited Partnership bought a new stake in shares of DBV Technologies in the 3rd quarter valued at about $519,000. Octagon Capital Advisors LP purchased a new stake in shares of DBV Technologies in the 2nd quarter worth approximately $9,315,000. Finally, MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter worth approximately $9,649,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Stock Down 1.0%

Shares of DBVT opened at $21.87 on Monday. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -4.23 and a beta of -0.97. DBV Technologies S.A. has a twelve month low of $3.91 and a twelve month high of $26.18. The company has a 50 day moving average of $20.93 and a two-hundred day moving average of $16.17.

Analyst Ratings Changes

DBVT has been the topic of several research reports. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a report on Thursday, December 18th. Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a research report on Wednesday, December 17th. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a report on Sunday, February 8th. Guggenheim reissued a “buy” rating and issued a $51.00 price target (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.25.

Insider Buying and Selling at DBV Technologies

In other news, major shareholder Bpifrance Epic sold 1,292,103 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $4.19, for a total value of $5,413,911.57. Following the completion of the sale, the insider owned 7,303,369 shares of the company’s stock, valued at $30,601,116.11. This trade represents a 15.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 3,369,627 shares of company stock valued at $15,489,908. 1.44% of the stock is owned by company insiders.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.